Phaseline

Targets › SSTR

SSTR: drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: the race on SSTR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sLu-DOTA-TATE
Somatostatin receptor agonist radiopharmaceutical (Lutetium-177 octreotate)
SSTRPhase 2Neuroendocrine CarcinomaDec 2027
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAl18F-octreotide
Somatostatin receptor (SSTR) imaging agent; Al18F-labeled octreotide for PET/CT imaging
SSTRPhase 2SSTR Positive TumorsDec 2028
ITM SolucinLutetium Lu 177 Edotreotide
SSTR-targeting radiopharmaceutical therapy delivering Lu-177 radiation
SSTRPhase 1Somatostatin Receptor PositiveJun 2028

Conditions

Neuroendocrine Carcinoma (1) Somatostatin Receptor Positive (1) SSTR Positive Tumors (1)

Modalities

protein or peptide (2)

Companies

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) ITM Solucin (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.